ARCHIVES

Clinical Trial Pathology Improvements Recommended By Group Remaining Actions After Merit Review

This article is from The Cancer Letter archive.

Vol. 05 No. 02 | January 12, 1979

Download PDF Visit The Full Archive

Related Articles

Amgen Pays $24.9 Million To Settle Kickback Charges

April 19, 2013

In Brief: Daniel Nixon Of Emory to Head Prevention Program; Henderson To Get Rosenthal Award

January 30, 1987

NCI Considers ‘Decentralization’ Of Group C To Provide Wider Access, Local Flexibility

September 7, 1990

Wyden Plans Bill To Induce Drug Firms to conduct Trials

October 29, 1993

Central Europe Faces Massive Public Education, Environmental Problems, Related To Cancer

August 23, 1991

NCAB Approves Fallout Study On Split Vote

March 13, 1981